Eye Cancer Treatment Market is Segmented By Treatment (Brachytherapy, External Radiotherapy, Enucleation, Chemotherapy, Others), By Drugs (Pembrolizumab, Ipilimumab, Dacarbazine, Temozolomide, Others), By Type (Eye melanoma, Squamous cell carcinoma, Retinoblastoma, Rhabdomyosarcoma), By Route of Administration(Oral, Intravenous, Tropical, Others), By End User(Hospital, Clinics, Cancer centers, Diagnostic centers, Ambulatory surgical centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Report Overview
Eye Cancer Treatment Market is Expected to reach at a CAGR of 7% during the forecast period (2024-2031).
Eye melanoma or cancer is formed when pigment producing cells in the eyes divide and multiply too rapidly forming a lump of tissue called tumor. It can occur due to continue exposure to ultraviolet radiation.
Eye Cancer Treatment Market
|
Metrics |
Details |
|
Market CAGR |
7% |
|
Segments Covered |
By Treatment, By Drugs, By Type, By Route of Administration, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Eye Cancer Treatment Market Dynamics
Eye cancer treatment market growth is driven by the increasing instances eye cancer cases across the globe, increase in awareness of treatment option for eye cancer cases,favorable reimbursement polices and increase in government funding in healthcare sectors.
The increase in prevalance of eye cancer cases in the market will drive the market growth
The global eye cancer treatment market is being driven by an increase in the incidence of eye cancers, an increase in healthcare expenditure, and an increase in risk factors such as the geriatric population. Furthermore, a rise in demand for innovative treatments, such as advanced surgeries, and high government investment are expected to propel the global market during the forecast period.
According to the American Cancer Society, there will be 3,360 new cases of eye and orbit cancer in 2019, with 1,860 men and 1,500 women. In addition, 370 deaths from eye and orbit cancers are expected in the same year, with 200 men and 170 women affected. Every year, 750 cases of ocular cancer are diagnosed in the United Kingdom, according to the NHS.
Eye Cancer, according to organisations such as the World Health Organization (WHO) and the American Cancer Society (ACS), are on the rise, necessitating the development of novel and effective eye cancer therapeutics. Technological advancements resulting in continuous innovation, as well as an increase in awareness about eye cancer symptoms and common causes, are expected to boost the global eye cancer treatment market. The rise in secondary eye cancers, as opposed to primary eye cancers, is expected to boost the global market in the coming years.
Furthermore, the prevalence of eye cancer is increasing at a steady rate in developed countries. This contributes to the growth of the global eye cancer treatment market.
High cost of diagnosis is likely to hamper the market growth
High cost of treatment is the major drawback which is likely to hamper the market . Majority of under developed and developing countries are facing this problem due to less share from the government sector. The high cost of anti-cancer drugs is a major issue for citizens in many countries. There is a lot of pressure to cut costs and show value. Political uncertainty and persistent economic stress in many countries are jeopardizing public health care funding. In less developed countries, a lack of cost-effective drugs has influenced population health and resulted in a low average life expectancy.
COVID-19 Impact Analysis
The COVID-19 has slight negative impact on the global eye cancer treatment market in 2020, as the number of diagnosed patients decreased. Due to limited access to health care, the focus on COVID-19 resulted in delays in cancer screening, diagnosis, and treatment. The drop in cancer diagnoses will very certainly be followed by a rise in late-stage diagnoses and cancer deaths that could have been avoided. During the pandemic, the American Cancer Society and other groups advocated routine cancer screenings and other elective medical procedures to detect eye cancer early. During the pandemic, however, lockdown and travel prohibitions made it difficult for many to acquire cancer diagnoses. Furthermore, due to the second wave of the COVID-19 and the emergence of deadlier variations of the COVID-19, the market recovery was interrupted in the first and second quarters of 2021. Furthermore, the threat of the third wave of the COVID-19 in the fourth quarter of 2021, as well as an increase in cases of delta-variants, are likely to stymie the global eye cancer treatment market's recovery.Novartis AG,Spectrum Pharmaceuticals , Inc, GlaxoSmithKline plc, Bayer AG, Amgen ,Inc, Takeda Pharmaceuticals Company Limited ,Eli Lilly and Company ,AstraZeneca, F. Hoffmann-La Roche Ltd, Janssen Global Servies ,LLC, Sanofi, and other prominent players are the leading players in the global thyroid cancer diagnostics Companies in the thyroid cancer diagnostics market are always working to increase customer awareness, launch new breakthroughs, improve existing technology, and develop new methods and techniques in order to expand their market share.
Eye Cancer Treatment Market Segment Analysis
The Orbit tumor segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
The global eye cancer treatment market can be divided into four types: eye melanoma, squamous cell carcinoma, orbit tumour, retinoblastoma, and Rhabdomyosarcoma.
Corneal cancer is a type of squamous cell carcinoma of the conjunctiva, which is a type of malignant tumour that occurs in the thinning of the eyeballs and eyelids. An orbital tumour develops in the orbit, which is the bony socket that houses the eye. Orbital tumours can be malignant or benign, and they can be primary or metastatic.
The two most dangerous orbital tumours are rhabdomyosarcoma and retinoblastoma. Retinoblastoma is a type of cancer that begins in the retina. It is most common in children and is frequently passed down from parents. The carcinoma of the eyelid is a type of eyelid tumour that develops in the sebaceous gland.
Eye Cancer Treatment Market Geographical Analysis
North America region holds the largest market share of global eye cancer treatment market
North America is expected to dominate the global market over the forecast period. This is due to the widespread use of advanced treatment methods and the high prevalence of eye cancer. North America is the most promising market for eye cancer treatment due to favorable reimbursement landscape, aggressive awareness programmes, improved diagnostic measures, and the presence of major advanced therapy brands. Europe is a significant market for eye cancer treatments due to the availability of treatment methods, the high income of the population, and an increase in the demand for effective treatment.
During the forecast period, the Asia Pacific eye cancer treatment market is expected to expand rapidly. Increased healthcare spending, rapid expansion of the healthcare industry, and high unmet needs are expected to drive the region's market during the forecast period. Technological advancements in the treatment of eye cancers, as well as an increase in disposal income, are expected to propel the Asia Pacific eye cancer treatment market during the forecast period. Furthermore, the geriatric population is growing in Asia Pacific's densely populated countries, which is a risk factor for eye cancer. During the forecast period, this is expected to boost the global eye cancer treatment market. According to the American Academy of Ophthalmology, Asians and people of color have a lower incidence of eye melanoma.
Eye Cancer Treatment Market Competitive Landscape
The eye cancer treatment market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Novartis AG, Spectrum Pharmaceuticals, Inc, GlaxoSmithKline plc, Bayer AG, Amgen ,Inc ,Takeda Pharmaceuticals Company Limited ,Eli Lilly and Company, AstraZeneca, F. Hoffmann –La Roche Ltd, Janssen Global Services, LLC , Sanofi ,Abbvie, Inc, Pfizer.Inc, Merck & Co, Inc.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the papillary thyroid carcinoma treatment market globally. For instance, the US Food and Drug Administration (FDA) has approved investigated new drug application of Modulation Therapeutics to commence human trial of its drug , MTI -201 , to treat uveal melanoma.
Novartis AG
Overview: Novartis AG manufactures pharmaceutical and consumer healthcare products. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company focuses on three divisions namely Pharmaceuticals, eyecare and generic medicines.
Product Portfolio:
Pembrolizumab: Keytruda is the brand name for pembrolizumab. It is used in cancer immunotherapy to treat melanoma of the eye. It is injected slowly into a vein. Pembrolizumab is an immunotherapy drug. It boosts the immune system's ability to fight cancer cells. Pembrolizumab targets and inhibits PD-1, a protein found on the surface of certain immune cells known as T-cells. By inhibiting PD-1, T-cells are activated to seek out and destroy cancer cells.
Frequently Asked Questions
What is the Projected CAGR value of the Eye Cancer Treatment Market?
Eye Cancer Treatment Market is expected to grow at a CAGR of 7% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Eye Cancer Treatment Market during 2022-2029
Which is the fastest growing region in the Eye Cancer Treatment Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
